Testing an immune-boosting TB vaccine in people with or without HIV
Part of Infections clinical trials.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 12 to 55 when you enroll
- Have a participating study site/clinic follow you for the whole study
- Be able to give consent (or have a parent/guardian for ages under 18, plus your written “assent” when required)
- Have had BCG vaccine only in infancy (not later)
- Be willing to share your HIV test results and participate in HIV prevention counseling if you don’t have HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether MTBVAC can safely protect newborn babies from tuberculosis and whether it helps the baby’s immune system learn to fight TB. If you enroll, the goal is to see safety and immune response in real newborn settings in sub-Saharan Africa.
This study tests a daily combination of two medicines, rifapentine and isoniazid (called 1HP), to prevent tuberculosis (TB) in children under 13 years old. It includes children who have been exposed to TB or are at high risk, both those living with HIV and those without HIV.
This study measures how strongly your immune system responds to COVID-19 vaccines. It includes people with newly diagnosed tuberculosis and a healthier comparison group, aiming to understand vaccine immune effects and safety.
This trial tests a two-drug HIV treatment (dolutegravir and lamivudine) for people who also have active TB and are taking a standard TB medicine called rifampin. It is designed for those who have not yet started HIV treatment.
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
This study tests a new tuberculosis vaccine called Lipovaxin in healthy adults aged 18–40. Researchers want to see if it is safe and how the body responds to it, which could help prevent TB infection in the future.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.